Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc. > well just maybe
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1507)
•••
Comment by wildbird1on Oct 26, 2023 11:13am
214 Views
Post# 35702151

RE:RE:RE:RE:RE:RE:RE:RE:RE:well just maybe

RE:RE:RE:RE:RE:RE:RE:RE:RE:well just maybe
Rumpl3StiltSkin wrote: There was an article ~5 years or so ago posted on this board about the growth of the nmibc market by now.  Market sales were to be between $500Mil and $1Bil US per year. So, assuming raw sales on the ~15% late stage share of this available to TLT, I estimated  $8 a share value. Using a conservative x16 of raw sales, not EBITA. It might be slightly more or less than that now with more dilution, maybe the market is actually larger than those estimates? 


Rumpl3StiltSkin, your numbers could be a little concervative (which is good).

But if you read the last Poster Presentation (10-23-2023) Page 6...
TLT said  " Market opportunity for Bladder cancer estimated between $1.1 to $7.2 Billion annually (Global market)".

And the most beautifull part is that Brain & Lungs cancer will add a lot's of $$$$$ to this story.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities